Therapy News and Research

RSS

Teva second quarter net sales increase 11% to $4.2 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2011.

27 Jul 2011

Early initiation of HIV therapy would save money, lives of South Africans

If the South African government followed a recent recommendation by the World Health Organization to start antiretroviral therapy (ART) for HIV-infected residents earlier in the progress of the disease, the policy shift would start saving the country money after 16 years and would extend thousands of lives for dozens of years, according to a new study.

27 Jul 2011

Male sex hormones can protect men from inflammatory diseases

It's all down to the testosterone: men are usually more muscular than women, they have deeper voices and more body hair. And - men are less susceptible to inflammatory diseases and allergies than women. This is also due to the male sex hormones as pharmacists at the Friedrich Schiller University Jena have shown in a recent study.

27 Jul 2011

High-dose vitamin D reduces musculoskeletal pain in breast cancer patients

High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.

27 Jul 2011

Interpersonal relationships in individuals with generalized anxiety disorder: Study

Most people worry from time to time. A new research study, led by a Case Western Reserve University faculty member in psychology, also shows that worrying can be so intrusive and obsessive that it interferes in the person's life and endangers the health of social relationships.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

NSU, Immunotec collaborate to determine effects of Immunocal on children with ASD

Immunotec Inc. announces that Nova Southeastern University (NSU) in Florida is conducting a study to determine the effects of Immunocal on the behaviours of children with autism spectrum disorder.

27 Jul 2011

NeurOp receives NIH grant to support research program for ischemia

NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.

27 Jul 2011

PACA study: Adrenaline can treat cardiac arrest

Adrenaline has kept its place in cardiac arrest guidelines despite limited evidence for or against its use. The PACA study by Jacobs and colleagues, soon to be published in Resuscitation, the official journal of the European Resuscitation Council, provides the best evidence to date supporting the use of adrenaline to treat cardiac arrest.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2011 results.

26 Jul 2011

Substances found in cigarette smoke damage blood vessels' endothelial cells

A research term headed by David Bernhard from the University Department of Surgery at the Medical University of Vienna has found out that substances found in cigarette smoke lead to blood vessels' endothelial cells constantly digesting themselves.

26 Jul 2011

Late-stage prostate tumors are driven by different hormonal pathway

UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.

26 Jul 2011

Key risk factors for death, transplantation in children with dilated cardiomyopathy

Researchers have identified important risk factors for death and transplantation in children with dilated cardiomyopathy, according to results from a study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

26 Jul 2011

THERAPY trial to evaluate benefits of catheter-based intervention for acute ischemic stroke

During the opening session of the SNIS Annual Meeting, J Mocco, MD, MS, Assistant Professor of Neurosurgery at The University of Florida in Gainesville, FL, announced the IDE approval and initiation of THERAPY, an industry-sponsored randomized controlled trial designed to prove the clinical benefit of interventional treatment of acute ischemic stroke.

26 Jul 2011

Covidien third quarter net sales increase 14% to $2.93 billion

Covidien plc today reported results for the third quarter of fiscal 2011. Net sales of $2.93 billion increased 14% from the $2.56 billion reported in the third quarter a year ago.

26 Jul 2011

New hope for infants born with Spinal Muscular Atrophy

Researchers in Ottawa report new hope for the treatment of infants born with serious genetic disorder.

26 Jul 2011

New potential anti-tumor agents might effectively treat mesothelioma

Researchers from the lab of Antonio Giordano, M.D., Ph.D., the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, have identified new potential anti-tumor agents that might be effective in treating mesothelioma, one of the deadliest cancer tumors.

26 Jul 2011

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm's ALS human clinical trials in the United States.

26 Jul 2011